Latest news
2 November 2018
Touchlight awarded runner-up in Spectator Economic Disruptor Award
Earlier this year, The Spectator and Julius Baer launched the inaugural Economic Disruptor Awards to celebrate the most creative entrepreneurs in the UK. Over the past six months, over 100 nominations have been reviewed. On the 1st of November, the winners were announced at a gala dinner hosted by Andrew Neil, Chairman of The Spectator, and attended by … Continued
24 October 2018
Touchlight announces collaboration with Janssen Biotech
Hampton, London, United Kingdom, 23rd October 2018 Touchlight Genetics Ltd., a biotechnology company developing a novel, synthetic DNA vector platform known as “doggybone” DNA, announced a collaboration with Janssen Biotech, Inc. to evaluate the application of doggybone DNA in the development of multiple genetic therapies, in the fields of infectious disease and oncology. The agreement … Continued
27 March 2018
Touchlight opens GMP production facility
Touchlight Genetics Ltd has established a GMP facility to support development of therapeutic products that incorporate the company’s revolutionary dbDNA™ vector technology. The facility will support clinical and commercial production for both in-house and partnered programs. Touchlight has developed a revolutionary DNA vector known as doggybone™ DNA (dbDNA) which enables uniquely differentiated products across multiple … Continued
6 December 2017
Touchlight cited in life sciences sector deal
Today, the UK government has announced that they have agreed with the life sciences sector a transformative new Sector Deal as a part of the Industrial Strategy. The Life Sciences Sector Deal will help ensure new pioneering treatments and medical technologies are produced in the UK, improving patient lives and driving economic growth. The deal … Continued
6 December 2017
Touchlight receives grand funding for DNA templated nanowire inks project
Touchlight and Newcastle University – DNA templated compound semiconductor nanowires for low-cost pollution sensors and quantum dots Touchlight and Newcastle University have been awarded grant funding from the UK’s innovation agency, Innovate UK, to advance a commercial manufacturing process to produce ultra-thin compound semiconductor nanowires using a DNA template. The process produces nanowire ‘inks’ that … Continued
21 August 2017
Touchlight expands world leading DNA technology into bespoke laboratories in Hampton
Touchlight moves into custom-designed laboratories within the restored Hampton Water Works situated on the River Thames. Touchlight’s operations are expanding in order to support numerous commercial product collaborations with large pharmaceutical and biotechnology companies around the world. This grade-two listed facility was formed in 1852 by Joseph Quick in response to the London Cholera epidemics, … Continued
7 December 2016
Touchlight shortlisted for London Award for Innovation
We are delighted to announce that Touchlight has been shortlisted for the London Award for Innovation in the 25th Anniversary London First Awards. See full article here. London First are a non-profit organisation with the mission to make London the best city in the world to do business. They aim to influence national and local government … Continued
4 August 2016
Touchlight shortlisted for Best Emerging UK Synthetic Biology Company.
We are delighted to announce that Touchlight has been shortlisted for the OBN 2016 Best Emerging UK Synthetic Biology Company. The OBN Awards celebrate innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors. A judging panel comprising a range … Continued
17 June 2016
Innovate UK funds Touchlight collaboration with Cobra to optimise AAV manufacture
Cobra Biologics Ltd (Cobra), international CDMO of biologics and pharmaceuticals, and Touchlight, a London based emerging biotech with a novel enzyme technology for large scale production of DNA, are collaborating on a project to optimise the manufacture of Adeno-Associated Virus (AAV) vectors used in the delivery of gene therapy treatments. The collaboration aims to evaluate … Continued